The Critical Role of Validation in Health Economic Modeling

By João L. Carapinha

January 24, 2024

In this article, we review an editorial by Stephanie Harvard in PharmacoEconomics. It’s all about the crucial role of stakeholder involvement in health economics modeling. Let’s unpack the three key takeaways from this editorial and then explore some alternative viewpoints including validation in health economic modeling .

Elaborated Key Takeaways:

1. Critical Role of Diverse Stakeholders: Stephanie presents why diverse stakeholder involvement is vital. She argues that when stakeholders from various backgrounds—patients, policymakers, clinicians—collaborate, the resulting models are more reflective of real-world needs. It’s not just about gathering opinions; it’s about integrating these insights into models that shape health policy and practices.

2. Complexities of Standardizing Stakeholder Involvement: Stephanie acknowledges the complexity in standardizing stakeholder involvement. She explores the balance between having enough diversity and maintaining manageability in the process. It’s a delicate act, ensuring all voices are heard while also keeping the modeling process efficient and focused.

3. Advancing Participatory Modeling: The article goes further, advocating for the health economics community to actively foster an environment where stakeholder participation isn’t just an afterthought. Stephanie envisions a culture where participatory modeling becomes the norm, driven by supportive policies and community practices.

Validation in Health Economic Modeling

In discussing stakeholder involvement, Stephanie surprisingly doesn’t discuss validation methods. In a field where empirical evidence is paramount, understanding how these inclusive models are validated is crucial.

Validation in modeling is crucial for several reasons:

  1. Accuracy: Validation ensures the model accurately represents the real-world system it’s designed to emulate. This is vital for the model’s credibility and usefulness in decision-making.
  2. Reliability: It tests the reliability of the model’s predictions, confirming that the model consistently produces reasonable and repeatable results.
  3. Confidence Building: By validating a model, stakeholders can have confidence in its predictions, which is essential when models are used to inform significant decisions or policies.
  4. Identifying Errors: Validation helps identify and correct errors in the model, whether in the assumptions, data inputs, or computational processes.
  5. Adaptability: It allows for the assessment of a model’s adaptability to different scenarios and conditions, ensuring its applicability in various contexts.

Academic and Government Disconnect

Moving to the next point, my sense is that academics and governments, the usual suspects in stakeholder discussions, might be too removed from the on-the-ground realities. While their expertise is invaluable, they should be actively engaging with a broader range of stakeholders, not just dictating models from an ivory tower.

Plurality in Modeler’s Values

Regarding the modeler’s values, Stephanie’s assumption of representing a singular reality through stakeholder collaboration is contentious. In reality, there are multiple perspectives, each valid in its own right. A more pluralistic approach, embracing a variety of thoughts and ideas, might be more effective than trying to adhere to a perceived ‘universal’ reality. This diversity could lead to richer, more adaptable models that are truly representative of the complex healthcare landscape. In the process, Stephanie seems to undervalue the input from small, homogenous groups. There’s a risk that her approach could lead to cumbersome, bureaucratic processes, potentially causing delays on patient access to innovative technologies. Also, setting a minimum standard for stakeholder involvement might not be necessary. In a market of ideas, let the best models naturally attract attention and resources, and let those be implemented.

Conclusion

In summary, Stephanie’ article prompts a vital discussion on stakeholder involvement in health economics modeling. It challenges us to think beyond traditional methods, advocating for inclusivity and diversity. Yet, it also opens the door for debate on the practicality and philosophical underpinnings of such approaches. It’s a conversation that’s as challenging as it is necessary in our pursuit of models that truly reflect the multifaceted nature of healthcare.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.